Results
1 -
10 of
30
(Click
here to explore results)
- FLT3 inhibitors for acute myeloid leukemia: successes, defeats, and emerging paradigms. Baku Acharya, Debasmita Saha, Daniel Armstrong, Naga Rajiv Lakkaniga, Brendan Frett
, RSC Med. Chem.
, 2022
, 13
, 798
- Indole-containing pharmaceuticals: targets, pharmacological activities, and SAR studies. Wei Zeng, Chi Han, Sarah Mohammed, Shanshan Li, Yixuan Song, Fengxia Sun, Yunfei Du
, RSC Med. Chem.
, 2024
, 15
, 788
- Protein kinase inhibition of clinically important staurosporine analogues. Osman A. B. S. M. Gani, Richard A. Engh
, Nat. Prod. Rep.
, 2010
, 27
, 489
- Dual FLT3/haspin kinase inhibitor based on 3H-pyrazolo[4,3-f]quinoline scaffold with activities against acute myeloid leukemia. Allison L. Kempen, Nickolas R. Brauer, Herman O. Sintim
, RSC Med. Chem.
, 2023
, 14
, 1743
- Indolocarbazole natural products: occurrence, biosynthesis, and biological activity. César Sánchez, Carmen Méndez, José A. Salas
, Nat. Prod. Rep.
, 2006
, 23
, 1007
- The synthesis of biologically active indolocarbazole natural products. George E. Chambers, A. Emre Sayan, Richard C. D. Brown
, Nat. Prod. Rep.
, 2021
, 38
, 1794
- Towards a RIOK2 chemical probe: cellular potency improvement of a selective 2-(acylamino)pyridine series. Christopher B. Wang, Álvaro Lorente-Macías, Carrow Wells, Julie E. Pickett, Alfredo Picado, William J. Zuercher, Alison D. Axtman
, RSC Med. Chem.
, 2021
, 12
, 129
- Phosphoryl- or phosphinoyl-functionalized benzo[de]isoquinolinones: synthesis, experimental design, mechanism and biological activity. Bettina Rávai, Nóra Popovics-Tóth, Kinga Komka, István Csontos, Bálint Szokol, Zoltán Őrfi, László Őrfi, Erika Bálint
, React. Chem. Eng.
, 2024
, 9
, 583
- Coumarin–carbazole based functionalized pyrazolines: synthesis, characterization, anticancer investigation and molecular docking. Mrugesh Patel, Nilesh Pandey, Jignesh Timaniya, Paranjay Parikh, Alex Chauhan, Neeraj Jain, Kaushal Patel
, RSC Adv.
, 2021
, 11
, 27627
- Natural product and natural product derived drugs in clinical trials. Mark S. Butler, Avril A. B. Robertson, Matthew A. Cooper
, Nat. Prod. Rep.
, 2014
, 31
, 1612